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LRH-1 mediates anti-inﬂammatory and antifungal
phenotype of IL-13-activated macrophages through
the PPARg ligand synthesis
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Liver receptor homologue-1 (LRH-1) is a nuclear receptor involved in the repression of
inﬂammatory processes in the hepatointestinal tract. Here we report that LRH-1 is expressed
in macrophages and induced by the Th2 cytokine IL-13 via a mechanism involving STAT6.
We show that loss-of-function of LRH-1 in macrophages impedes IL-13-induced macrophage
polarization due to impaired generation of 15-HETE PPARg ligands. The incapacity to
generate 15-HETE metabolites is at least partially caused by the compromised regulation of
CYP1A1 and CYP1B1. Mice with LRH-1-deﬁcient macrophages are, furthermore, highly
susceptible to gastrointestinal and systemic Candida albicans infection. Altogether, these
results identify LRH-1 as a critical component of the anti-inﬂammatory and fungicidal
response of alternatively activated macrophages that acts upstream from the IL-13-induced
15-HETE/PPARg axis.
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M
acrophages orchestrate innate immune responses by
initiating and resolving inﬂammatory signalling pro-
grammes. Emerging evidence indicates that the state of
macrophage polarization plays a critical role in the regulation of
these inﬂammatory processes. Two different programmes of
macrophage activation, the classical (M1) and the alternative
differentiation, classify polarized macrophages with either
persistence or resolution of inﬂammation1–3. M1 macrophages
express high levels of opsonic receptors, involved in the
production of pro-inﬂammatory effector molecules such as
reactive oxygen and nitrogen intermediates and pro-
inﬂammatory cytokines (interleukin (IL)-1b, tumour-necrosis
factor alpha (TNFa), IL-6 and IL-12). These macrophages
contribute to inﬂammation, microbial killing, regulation of cell
proliferation and apoptosis. Alternatively activated macrophages
are characterized by abundant levels of the anti-inﬂammatory
cytokine IL-10 and non-opsonic receptors, such as C-type lectin
receptors and scavenger receptors (CD36), and resolve
inﬂammation by increasing CD36-mediated efferocytosis and
secretion of tissue remodelling/repair mediators3,4.
The balance of macrophage differentiation in favour of
alternatively activated macrophages can be shifted by the activation
of the nuclear receptor peroxisome proliferator-activated receptor
gamma (PPARg) (refs 5,6). PPARg expression and activity in
macrophages is negatively regulated during inﬂammatory
processes7,8. In addition, activated PPARg transrepresses many
inﬂammation-activated transcription factors, including nuclear
factor-kappaB (NF-kB), signal transducers and activators of
transcription (STATs), activator protein 1 (AP1) and nuclear
factor of activated T-cells NFAT), resulting in pro-inﬂammatory
mediator inhibition9. PPARg is activated by endogenous ligands
derived from the metabolism of arachidonic acid (AA)9. Among
these ligands, 15-deoxy-D12,14PGJ2 (15d-PGJ2), metabolized
through the COX1/COX2 cyclooxygenases, and the 12- and 15-
hydroxyeicosatrienoic acids (HETEs), metabolized through 5 and
12/15 lipoxygenases, are essential for PPARg endogenous
activation5,10,11. In addition to cyclooxygenases and lipoxygenases,
cytochrome P450 (CYP) enzymes are also considered to be critical
for the metabolism of AA in epoxy (EETs) and in hydroxy (HETEs)
derivatives10,11. Within the CYP family, the CYP1 family is mainly
involved in the generation of 12- and 15-HETEs through CYP1A1
and CYP1B1 (refs 12,13).
Liver receptor homologue-1 (LRH-1, NR5A2) is a nuclear
receptor highly expressed in the intestine, liver, pancreas and
ovary14,15. Although LRH-1 has been recognized as an orphan
receptor, phospholipids, including the phosphatidyl inositol second
messengers, and more recently the 12C-fatty acyl-containing
phospholipid, dilauroyl phosphatidylcholine (DLPC), have been
described to bind the ligand-binding pocket and to
act as LRH-1 agonists16–18. LRH-1 plays important roles
in embryonic development, cholesterol and bile acid
homeostasis14,15 and promotes hepatic glucose sensing through
the regulation of the glucokinase enzyme19. Several lines of evidence
also support a role for LRH-1 in the control of the inﬂammatory
response. While pro-inﬂammatory factors such as TNFa and
lipopolysaccharide (LPS) decrease LRH-1 expression in murine
models of human colon tumorigenesis, deﬁciency of LRH-1 in the
intestinal epithelium predisposes mice to intestinal inﬂammation as
a result of a defect in local glucocorticoid production. In the colon
from patients with inﬂammatory bowel disease, inﬂammation is
inversely correlated with the expression of LRH-1 (refs 20,21). In
line with these reports, Venteclef et al.22,23 identiﬁed a role for
LRH-1 in the negative modulation of the hepatic acute-phase
response by inhibiting IL-6- and IL-1b-stimulated haptoglobin,
serum amyloid A gene expression in hepatocytes and inducing anti-
inﬂammatory IL-1ra expression. Despite the numerous studies
documenting the anti-inﬂammatory properties of LRH-1 in the
liver and gut, no studies so far have focused on the role of LRH-1 in
macrophages.
In the present study, we identify LRH-1 as an important
regulator of the inﬂammatory response in macrophages. We
demonstrate that LRH-1 is induced by IL-13 via a STAT6-
dependent mechanism, which in turn induces the transcriptional
activation of CYP1A1 and CYP1B1, two enzymes involved in the
generation of 15-HETE PPARg ligand. Finally, we also demonstrate
the importance of intact LRH-1 signalling in the anti-inﬂammatory
and antifungal functions of alternatively activated macrophages,
indicating that modulators of LRH-1 activity may have therapeutic
potential to restrain infectious and inﬂammatory diseases.
Results
IL-13-mediated LRH-1 gene expression is dependent on STAT6.
The anti-inﬂammatory properties of LRH-1 are well established
in the liver and gut24. To elucidate whether LRH-1 also
participates in regulating the inﬂammatory response in
macrophages, gene expression proﬁling was performed. In situ
hybridization and reverse transcriptase–quantitative PCR
(RT–qPCR) revealed that LRH-1 (encoded by the Nr5a2 gene),
known to be expressed in the colon and liver, is also expressed in
macrophages but not in B and T immune cells (Fig. 1a).
Consistent with the gene expression data, LRH-1 protein was also
detected in macrophages (Supplementary Fig. 1b). We next
analysed the impact of pro- and anti-inﬂammatory factors on
Nr5a2 gene expression in primary macrophages. As depicted in
Fig. 1b, pro-inﬂammatory challenges, such LPS and IFNg
exposure, but not IL-6, signiﬁcantly reduced or abolished Nr5a2
mRNA expression. Conversely, IL-13, IL-4 and IL-10 cytokines
signiﬁcantly enhanced Nr5a2 mRNA level in macrophages.
Similar to ﬁndings in the murine model, NR5A2 mRNA levels
were signiﬁcantly increased by IL-13 treatment in human
monocytes (Fig. 1c). These results suggest that LRH-1 could be
part of the transcriptional network mediating alternative
activation of macrophages. To test this hypothesis, we analysed
the downstream signalling components of IL-13 in more detail
(Fig. 1d–i). STAT6, a transcription factor known to be activated
by IL-13 is part of the signalling pathway that governs alternative
activation25. Interestingly, exposure of macrophages with AG490,
a Jak-2/STAT6 inhibitor, prevented the IL-13-mediated induction
of LRH-1 (Fig. 1d). Consistent with these observations, IL-13
failed to increase Nr5a2 mRNA and protein levels in
macrophages deﬁcient for STAT6 (Fig. 1e,f), suggesting that
STAT6 mediates the transcriptional regulation of LRH-1. We
then performed transient transfection assays in primary
macrophages to assess the effect of IL-13 and STAT6 on Nr5a2
promoter activity. While 4 h of IL-13 exposure was already
sufﬁcient to induce Nr5a2 promoter activity in wild-type
macrophages (Fig. 1g,h), chemical inhibition of STAT6 by
AG490 (Fig. 1g) or genetic deletion of STAT6 (Fig. 1h)
attenuated or even abolished this response.
To evaluate whether LRH-1 is subject to direct transcriptional
control by STAT6, we performed an in silico analysis of the Nr5a2
promoter region. Scanning of the Nr5a2 promoter sequence for
the STAT6 response element (STAT6-RE) canonical motif
revealed four putative STAT6-RE (Fig. 1i). Chromatin immuno-
precipitation (ChIP) analysis of macrophage DNA from C57BL/6
mice revealed speciﬁc recruitment of STAT6 to site 1 at  541,
which is most proximal to the transcription initiation site of the
gene (Fig. 1i).
To explore the functionality of this site, we next modiﬁed by
in vitro mutagenesis its sequence and we evaluated the mutated
Nr5a2 reporter construct activity on IL-13 exposure (Fig. 1j).
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Mutation of the STAT6-RE abolished the activity of the Nr5a2
reporter construct in response to IL-13 in Stat6þ /þ and
Stat6M / macrophages (Fig. 1j). These results demonstrate
that STAT6 directly controls the transcription of LRH-1 in
response to IL-13.
LRH-1 is involved in IL-13-induced macrophage activation. In
order to assess the role of LRH-1 in IL-13-induced alternative
macrophage differentiation, we generated mice in which the
Nr5a2 gene was selectively disrupted in myeloid-derived cells.
To generate these animals, mice carrying ﬂoxed Lrh-1 alleles
were crossed with transgenic mice that express the Cre
recombinase under the control of the mouse phagocyte-selective
lysozyme promoter21,26. Compared with control (Lrh-1Mþ /þ )
macrophages, LRH-1 mRNA and protein levels were almost
undetectable in macrophages derived from the myeloid cell-
speciﬁc LRH-1-deﬁcient (Lrh-1M / ) mice (Supplementary
Fig. 1a–c). Furthermore, the disruption of LRH-1 could not be
detected in other LRH-1-expressing tissues, such as the liver and
the colon (Supplementary Fig. 1d,e).
We then evaluated the expression of speciﬁc markers of
classical and alternative activation in untreated or IL-13-treated
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Figure 1 | IL-13-mediated LRH-1 gene expression is dependent on STAT6. (a) Nr5a2 mRNA expression in the colon, liver, peritoneal macrophages (MF),
B (LB) and T (LT) lymphocytes from C57BL/6 mice determined using RT–PCR. Inset shows in situ hybridization of Nr5a2 mRNA in peritoneal macrophages
from C57BL/6 mice (scale bar, 25mm). (b,c) Nr5a2mRNA expression in macrophages from C57BL/6 mice (b) and in human macrophages (c) treated with
the indicated cytokines for 4 h, determined using RT–PCR. The results were represented in fold induction relative to the untreated control or wild-type
littermate. (d,e) Nr5a2 mRNA expression in macrophages from C57BL/6 mice pretreated with AG490 and stimulated with IL-13 (d) and in macrophages
from Stat6þ /þ and Stat6 / mice stimulated with IL-13 for 4 h (e), determined using RT–PCR. The results were represented in fold induction relative to
the untreated control or wild-type littermate. (f) Immunoblot analysis of the nuclear expression of LRH-1 and TBP (Tata-binding protein) in macrophages
from Stat6þ /þ and Stat6 / mice stimulated with IL-13 for 24 h. (g,h) Luciferase activity in macrophages from C57BL/6 mice transfected with LRH-1
(LRH-1-luc) promoter construct pretreated with AG490 (g) or from Stat6þ /þ and Stat6 / mice (h), and treated with IL-13 for 24 h. The results were
represented in fold induction relative to the untreated control or wild-type littermate. (i) Schematic presentation of the four putative STAT6 response
elements in the mouse Nr5a2 promoter identiﬁed by Genomatix algorithm and assessment of STAT6 recruitment to site 1 and to the Arg1 promoter
determined with the ChIP analysis using genomic DNA from C57BL/6 macrophages treated with IL-13 for 4 h. (j) Luciferase activity in macrophages from
Stat6þ /þ and Stat6 / mice transfected with LRH-1 promoter constructs and treated with IL-13 for 18 h. The results were represented in fold induction
relative to the untreated control. Results correspond to mean±s.e.m. of triplicates. Data are representative of three independent experiments. *Po0.05
**Po0.01 compared with the respective untreated control and xPo0.05, xxPo0.01 compared with IL-13-treated wild-type littermate. P values were
determined using Bonferroni–Dunnett method.
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Lrh-1Mþ /þ and Lrh-1M / macrophages during 4 h. Overall,
Lrh-1M / macrophages displayed an upregulation of M1
markers such as Nos2 (encoding the inducible nitric oxide
synthase) and the Fcg-receptors Fcgr3 and Fcgr1 (encoding CD16
and CD64 proteins, respectively), which was mirrored by a
downregulation of Chi3l3 (YM1), Mrc1 (MR), Clec7a (Dectin-1),
Il1rn (IL-1ra) and Tgfb1 (transforming growth factor (TGF)-b1)
alternative activation markers (Fig. 2a,b). This was accompanied
by an increase in the mRNA and protein levels of the
inﬂammatory cytokines TNFa, IL-1b and IL-6 (encoded by
Tnfa, Il1b and Il-6 genes, respectively; Fig. 2a,c). Il12 pro-
inﬂammatory and Il10 anti-inﬂammatory cytokine mRNA levels
remained unchanged in Lrh-1Mþ /þ and Lrh-1M / macro-
phages (Fig. 2a). Furthermore, the induction of MR, Dectin-1,
CD36, Arg1 (encoding the arginase 1), Chi3l3 and Il1rn
expression by IL-13 was strongly diminished in Lrh-1M /
macrophages (Fig. 2a,b). Consistent with reduced alternative
activation markers in Lrh-1M / macrophages, the M1 markers
such as Nos2, Itgam (CD11b), Fcgr3, Fcgr1, Il1b and Il-6 still
remained highly expressed (Fig. 2a–c). Consistent with these
ﬁndings, the induction of alternative activation gene markers
observed after 4 h of IL-13 treatment was ampliﬁed after 24 h of
IL-13 treatment in Lrh-1Mþ /þ macrophages (Supplementary
Fig. 2a). Moreover, the decrease in alternative activation markers
in Lrh-1M / macrophages after 4 h of IL-13 treatment was
sustained after 24 h of stimulation (Supplementary Fig. 2a).
Altogether, these data indicate that LRH-1 is required for
repression of pro-inﬂammatory state and for optimal induction
of alternative macrophage activation by IL-13. These ﬁndings are
consistent with the robust induction of Il10, Tgfb1, Il1rn, Mrc1,
Clec7a and Cd36 gene expression in Lrh-1Mþ /þ macrophages
treated with the LRH-1 agonist DLPC (Supplementary Fig. 2b).
LRH-1 activates 15-HETE secretion via the control of CYP1s.
The nuclear receptor PPARg is a key component of the signalling
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Figure 2 | LRH-1 is involved in IL-13-induced alternative activation of macrophages. (a) Gene expression analysis of markers of M1 and M2 polarization
in peritoneal macrophages from Lrh-1Mþ /þ and Lrh-1M / mice treated with IL-13 for 4 h, determined using RT–PCR. The results were represented
in fold induction relative to the untreated Lrh-1Mþ /þ littermate. (b) Dot-plot representing Dectin-1, CD36 and MR protein expression in macrophages
from Lrh-1Mþ /þ and Lrh-1M / mice treated with IL-13 for 24 h. Numbers indicate the % of positive cells. Graphs represent geomean ﬂuorescence
quantiﬁcation for the indicated proteins. (c) Cytokine production of peritoneal macrophages from Lrh-1Mþ /þ and Lrh-1M / mice after IL-13 treatment
and C. albicans challenge for 8 h (ratio: 1 macrophage:3 yeasts), quantiﬁed by enzyme-linked immunosorbent assay. Results correspond to mean±s.e.m. of
triplicates. Data are representative of three independent experiments. *Po0.05, **Po0.01 compared to the respective untreated control and xPo0.05,
xxPo0.01 compared with Lrh-1Mþ /þ þ IL-13. P values were determined using the Bonferroni–Dunnett method.
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pathway triggered by IL-13 and directly controls the expression of
markers of alternative activation. To establish whether the
increase in alternative activation markers by IL-13 results from
direct regulation of PPARg transcription by LRH-1, we ﬁrst
evaluated Pparg mRNA levels in Lrh-1Mþ /þ and
Lrh-1M / macrophages under basal conditions and after
IL-13 exposure. The increased Pparg mRNA level by IL-13 in
Lrh-1Mþ /þ macrophages was not affected in Lrh-1M / mac-
rophages (Fig. 3a). Moreover, in transient transfection studies,
absence of LRH-1 in Lrh-1M / macrophages (Fig. 3b) or
conversely ectopic expression of LRH-1 in wild-type macro-
phages (Fig. 3c) did not signiﬁcantly affect IL-13-mediated
PPARg promoter induction, further indicating that LRH-1 does
not regulate the transcription rate of PPARg. Next, we examined
whether LRH-1 was required for PPARg activation by assessing
the impact of IL-13 on a heterologous PPARg reporter
transfected in Lrh-1Mþ /þ and Lrh-1M / macrophages.
Remarkably, while in Lrh-1Mþ /þ macrophages IL-13 sig-
niﬁcantly induced the PPRE luciferase reporter, no such response
could be observed in Lrh-1M / macrophages (Fig. 3d).
Conversely, co-transfection of the PPRE luciferase reporter with
an expression vector for LRH-1 robustly increased PPARg acti-
vation (Fig. 3e), suggesting that LRH-1 induces the activity of
PPARg.
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Figure 3 | LRH-1 activates CYP1A1- and CYP1B1-dependent 15-HETE production. (a) Pparg mRNA expression in macrophages from Lrh-1Mþ /þ and
Lrh-1M / mice treated with IL-13 for 4 h, determined using RT–PCR. The results were represented in fold induction relative to the untreated wild-type
littermate. (b) Luciferase activity in macrophages from Lrh-1Mþ /þ and Lrh-1M / mice transfected with PPARg (PPARg-luc) promoter construct and
treated with IL-13 for 4 h. The results were represented in fold induction relative to the respective control. (c) Luciferase activity in macrophages from
C57BL/6 mice co-transfected with PPARg (PPARg-luc) promoter construct in presence (LRH-1) or absence (empty) of LRH-1 (pCMX-LRH-1) and treated
with IL-13 for 4 h. The results were represented in fold induction relative to the untreated control (empty). (d) Luciferase activity in macrophages from
Lrh-1Mþ /þ and Lrh-1M / mice transfected with a PPRE (PPRE-luc) construct treated with IL-13 for 24 h. The results were represented in fold induction
relative to the respective untreated control. (e) Luciferase activity of macrophages from C57BL/6 macrophages co-transfected with PPRE (PPRE-luc)
construct in presence (LRH-1) or absence (empty) of LRH-1 (pCMX-LRH-1), treated with IL-13 for 24 h. The results were represented in fold induction
relative to the respective control. (f) Gene expression analysis of arachidonic acid metabolic enzymes in macrophages from Lrh-1Mþ /þ and Lrh-1M /
mice treated with IL-13 for 4 h, determined using RT–PCR. The results were represented in fold induction relative to untreated Lrh-1Mþ /þ . (g) Immunoblot
analysis of Cyp1b1 and Actin in macrophages from Lrh-1Mþ /þ and Lrh-1M / mice stimulated with IL-13 for 24 h. (h,i) Gene expression analysis of Alox15,
Cyp1a1 and Cyp1b1 in macrophages from Stat6þ /þ and Stat6 / mice treated with IL-13 (h) and in macrophages from Lrh-1M / and Lrh-1Mþ /þ
mice stimulated with DLPC for 4 h (i), determined using RT–PCR. The results were represented in fold induction relative to untreated wild-type littermate.
(j) 15-HETE production by macrophages from Lrh-1M / and Lrh-1Mþ /þ mice stimulated with or without IL-13 quantiﬁed by enzyme immunoassay (EIA).
The results were represented in fold induction relative to untreated Lrh-1Mþ /þ . (k) [3H]AA mobilization in membrane phospholipids of macrophages from
Lrh-1M / and Lrh-1Mþ /þ mice stimulated with IL-13 for 2 h. (l) 15-HETE production by macrophages from Alox15 / and Alox15þ /þ mice stimulated
with IL-13 for 24 h and silenced or not for Cyp1a1 and Cyp1b1 (siRNA Cyp) measured by EIA. The results were represented in fold induction relative to
respective untreated control (siRNA C). Results correspond to the mean±s.e.m. of triplicates. Data are representative of three independent experiments.
*Po0.05, **Po0.01 compared with the respective untreated control and xPo0.05, xxPo0.01 compared with the corresponding treated or untreated wild-
type littermate. P values were determined using Bonferroni–Dunnett method.
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PPARg is activated by endogenous ligands derived from the
metabolism of AA. The COX1/COX2 cyclooxygenases, 5 and
12/15 lipoxygenases and CYP enzymes are considered to be
critical for the conversion of AA into endogenous PPARg ligands.
To identify how LRH-1 may have an impact on PPARg
activation, we next explored whether LRH-1 can coordinate
PPARg ligand availability through the control of the expression of
these enzymes. The mRNA levels of Ptgs2 (cyclooxygenase 2),
Alox5 (5 lipoxygenase) and Hpgds (prostaglandin-D synthase)
after IL-13 stimulation were not differentially expressed in
Lrh-1Mþ /þ and Lrh-1M / macrophages (Fig. 3f). However,
IL-13 robustly induced Alox15 (12/15 lipoxygenase), Cyp1a1 and
Cyp1b1 gene expression in Lrh-1Mþ /þ macrophages, while this
induction was blunted in Lrh-1M / macrophages. Moreover,
Cyp1b1 protein levels were only induced in Lrh-1Mþ /þ
macrophages on IL-13 exposure, but not in Lrh-1M /
macrophages (Fig. 3g). Unlike Cyp1a1 and Cyp1b1 mRNA levels,
which were unresponsive to the IL-13 treatment in Lrh-1M /
macrophages, Alox15 expression was still moderately induced
(Fig. 3f), indicating that Alox15 is only partially controlled by
LRH-1.
Consistent with these ﬁndings, a strong decrease in Alox15,
Cyp1a1 and Cyp1b1 expression could be observed in both
untreated and IL-13-treated Stat6 / macrophages (Fig. 3h),
further supporting the importance of STAT6 in the regulation of
these genes.
To further explore whether STAT6 controls the expression of
Alox15, Cyp1a1 and Cyp1b1 directly or indirectly through the
induction of LRH-1, we performed an in silico analysis of Alox15,
Cyp1a1 and Cyp1b1 promoters (Supplementary Fig. 3a). This
analysis revealed one putative LRH-1 and two putative STAT6-
RE in the Alox15 promoter, with more than 95% of similarity to
the consensus REs. Scanning of the Cyp1a1 and Cyp1b1 promoter
sequences indicated the presence of conserved LRH-1 REs in both
promoters, while no conserved STAT6 REs (matrix similarity
o0.8) could be identiﬁed in these regulatory regions
(Supplementary Fig. 3a). Consistent with these ﬁndings, DLPC
treatment increased Alox15, Cyp1a1 and Cyp1b1 gene expression
in Lrh-1Mþ /þ macrophages, but not in Lrh-1M / macro-
phages (Fig. 3i). These data conﬁrm the importance of LRH-1 in
the regulation of Alox15, Cyp1a1 and Cyp1b1.
Finally, to assess whether these effects on gene expression also
translate into changes in endogenous ligand availability, 15-HETE
production was assessed. Interestingly, while IL-13 exposure
robustly enhanced 15-HETE levels in Lrh-1Mþ /þ macrophages,
this effect was completely lost in Lrh-1M / macrophages
(Fig. 3j). These ﬁndings indicate that LRH-1 is critically required
for IL-13-induced 15-HETE production in macrophages.
Importantly, IL-13-induced mobilization of AA was similar in
Lrh-1Mþ /þ and Lrh-1M / macrophages (Fig. 3k), indicating
that the generation of 15-HETE metabolites through LRH-1 is
dependent on AA metabolism.
To further dissect how LRH-1 promotes the production of
15-HETEs in response to IL-13, we assessed 15-HETE production
in Alox15-deﬁcient macrophages on Cyp1a1 and Cyp1b1 short
interfering RNA (siRNA)-mediated silencing (Fig. 3l and
Supplementary Fig. 3b). Interestingly, the increased 15-HETE
production by IL-13 was still conserved in Alox15 / macro-
phages. Furthermore, the simultaneous gene silencing for Cyp1a1
and Cyp1b1 in both Alox15 þ /þ and Alox15 / macrophages
abolished this induction (Fig. 3l). Altogether, these data indicate
that LRH-1 drives the generation of 15-HETE metabolites
through its impact on CYP1 gene expression.
To deﬁne whether Cyp1a1 and Cyp1b1 are direct transcrip-
tional targets of LRH-1, transfection assays in Lrh-1Mþ /þ and
Lrh-1M / macrophages were performed using a luciferase
reporter containing ±1.2 kb of the promoter of the Cyp1a1 and
Cyp1b1 genes. IL-13 exposure of Lrh-1Mþ /þ macrophages
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resulted in an eightfold increase in reporter activity of both
Cyp1a1 and Cyp1b promoters (Fig. 4a,c). Interestingly, genetic
deletion of LRH-1 abolished this response, demonstrating that
Cyp1a1 and Cyp1b1 promoters are directly activated by LRH-1.
To identify the critical LRH-1 REs in the Cyp1a1 and Cyp1b1
promoters, we mutagenized the putative RE that were found by in
silico analysis (Supplementary Fig. 3a), and their response to
LRH-1 on IL-13 exposure was compared (Fig. 4a–c). For the
Cyp1a1 promoter, mutation of the ﬁrst LRH-1 RE (site 1)
abolished the activity of the reporter construct in response to
IL-13, whereas mutation of site 2 was still responsive in
Lrh-1Mþ /þ macrophages (Fig. 4a). Furthermore, whole inhibi-
tion of mutated reporter construct activities in Lrh-1M /
macrophages established that site 1 is the principal site
transmitting the effect of LRH-1 on the Cyp1a1 promoter. Thus,
this result identiﬁed speciﬁc recruitment of LRH-1 to site 1, which
is most distal to the transcription initiation site in the Cyp1a1
promoter.
For the Cyp1b1 promoter, IL-13 treatment failed to increase the
activity of the mutated Cyp1b1 reporter in both Lrh-1Mþ /þ or
Lrh-1M / macrophages (Fig. 4c), indicating that LRH-1 binds
and activates the Cyp1b1 promoter through a unique sequence
between  742 and  728 bp upstream of the transcription
initiation site of the gene. Finally, ChIP assays were performed.
IL-13 enhanced the recruitment of LRH-1 on both Cyp1a1 and
Cyp1b1 sites in Lrh-1Mþ /þ macrophages, but not in Lrh-1M /
macrophages (Fig. 4b–d). Altogether, these results demonstrate
that LRH-1 directly binds Cyp1a1 and Cyp1b1 promoters and
hence controls the transcription of Cyp1a1 and Cyp1b1 genes in
response to IL-13.
LRH-1/CYP1-dependent 15-HETE release induces PPARc
activation. To further determine whether the generation of
15-HETE metabolites through LRH-1 are involved in PPARg
activation, we assessed whether supplementation of 15-HETE can
rescue the loss of PPARg activation in Lrh-1M / macrophages.
In contrast to IL-13, which could not induce PPARg activation
in Lrh-1M / macrophages, addition of exogenous 15-HETE
efﬁciently restored the induction of both a PPRE luciferase
reporter (Fig. 5a) and of PPARg target genes such asMrc1, Clec7a
and Cd36 (Fig. 5b) in Lrh-1M / macrophages, indicating that
the PPARg activation through LRH-1 is critically dependent on
15-HETE production.
To conﬁrm that 15-HETE production through the LRH-1/
CYP1 axis induces PPARg activation, we evaluated PPARg
activation in macrophages silenced for Cyp1a1 and Cyp1b1.
Interestingly, PPARg activity as determined by the induction of a
PPRE luciferase reporter (Fig. 5c) and the induction of PPARg
target genes (Fig. 5d) by IL-13 were totally inhibited in
macrophages deﬁcient for Cyp1a1 and Cyp1b1. Moreover, the
induction of a PPRE luciferase reporter (Fig. 5c) and of PPARg
target genes (Fig. 5d) was still signiﬁcantly enhanced by IL-13 in
Alox15 / macrophages, showing that the 12/15 lipoxygenase is
not required for PPARg activation mediated by LRH-1. These
data are in support of a critical role of CYP1A1 and CYP1B1 in
LRH-1-mediated PPARg activation through 15-HETE synthesis.
IL-13 activation of macrophages requires STAT6/LRH-1/PPARc.
To determine whether STAT6 controls both directly the tran-
scription of markers of IL-13-mediated alternative activation and
indirectly through the activation of the LRH-1/PPARg axis, we
studied the mRNA level of alternative activation markers in
STAT6-deﬁcient macrophages. IL-13-augmented induction of
Arg1, Chi3l3 (YM1), Retnla (Fizz1), MR, Clec7a and CD36 was
detected in Stat6þ /þ macrophages but not in Stat6 /
macrophages (Fig. 5e). The lack of IL-13-augmented induction of
alternative markers was associated with a failure of Stat6 /
macrophages to produce 15-HETE in response to IL-13 (Fig. 5f).
Interestingly, the addition of exogenous 15-HETE restored the
induction of alternative polarization markers in Stat6 /
macrophages and not in PpargM / macrophages (Fig. 5e and
Supplementary Fig. 3c). These data suggest that STAT6 is required
for induction of macrophage-alternative activation markers and
further support the existence of a PPARg-dependent mechanism in
the regulation of these genes.
Moreover, induction of Arg1, Retnla (Fizz1) and Chi3l3 (YM1)
in response to IL-13 was slightly decreased in PpargM /
macrophages, whereas the induction of Mrc1 (MR), Clec7a and
CD36 was completely abrogated in PpargM / macrophages
(Fig. 5g). These results indicate the existence of distinct regulatory
mechanisms involving either STAT6 with a modest contribution
of PPARg or predominantly controlled by the LRH-1/PPARg
axis. In line, the overexpression of Mrc1, Clec7a and Cd36 after
treatment with DLPC in PpargMþ /þ macrophages was not
detected in PpargM / macrophages (Fig. 5h), clearly establish-
ing that LRH-1 acts upstream from PPARg in the signalling
cascade leading to the PPARg-dependent gene expression.
IL-13-induced fungicidal properties of macrophages via LRH-1.
Previous work from our laboratory established the importance of
PPARg in the fungicidal functions of alternatively activated
macrophages27. On the basis of the current ﬁndings suggesting a
role for LRH-1 in PPARg-mediated alternative polarization
following IL-13 stimulation, we next investigated whether
deletion of LRH-1 in macrophages could have an impact on the
outcome of Candida albicans infection. The severe systemic
infection of mice with C. albicans resulted in a signiﬁcantly lower
survival rate of Lrh-1M / mice compared with Lrh-1Mþ /þ
mice (Po0.001; Fig. 6a), supporting a role for LRH-1 in
antifungal defence. To further explore the exact function of
LRH-1 in the pathophysiology of fungal infection, we evaluated
the fungal burden in the intestinal tract and the macrophage
microbicidal functions in a murine experimental model of
gastrointestinal candidiasis. Lrh-1M / mice infected with
C. albicans had more severe gastrointestinal infection than their
wild-type littermates and showed worsened fungal burden in
the caecum (Fig. 6b). Remarkably, IL-13, 15-HETE, as well as
DLPC, diminished C. albicans gastrointestinal colonization in
Lrh-1Mþ /þ mice. However, these effects were lost in Lrh-1M /
mice treated with IL-13 or DLPC, but not when the PPARg
ligand, 15-HETE, was administered to the animals (Fig. 6b).
To investigate whether LRH-1 in macrophages has any relevant
microbicidal phenotype, we evaluated the capacity of Lrh-1Mþ /þ
and Lrh-1M / macrophages to kill yeasts in vitro. Compared
with Lrh-1Mþ /þ macrophages, Lrh-1M / macrophages
showed a defect in their ability to kill C. albicans, demonstrating
the contribution of LRH-1 in macrophage-intrinsic antifungal
activity (Fig. 6c). Consistent with our observation, Lrh-1M /
macrophages were less efﬁcient in engulﬁng C. albicans and
producing reactive oxygen species (ROS) after fungal challenge
(Fig. 6d,e). Moreover, the defect of Lrh-1M / macrophages to
exert their antifungal activity was correlated with lower MR and
Dectin-1 protein levels after C. albicans challenge (Supplementary
Fig. 3d). As expected, treatment with IL-13 of Lrh-1Mþ /þ
macrophages increased the killing and the phagocytosis of
C. albicans and also ROS production in response to C. albicans.
These inductions were abrogated in Lrh-1M / macrophages,
underscoring the importance of LRH-1 in these fungicidal
functions (Fig. 6c–e). Similar effects were obtained when
macrophages were stimulated with DLPC (Fig. 6c–e).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7801 ARTICLE
NATURE COMMUNICATIONS | 6:6801 | DOI: 10.1038/ncomms7801 |www.nature.com/naturecommunications 7
& 2015 Macmillan Publishers Limited. All rights reserved.
Interestingly, treatment with 15-HETE increased the fungicidal
functions in both Lrh-1Mþ /þ and Lrh-1M / macrophages
(Fig. 6c–e). Moreover, treatment with IL-13, DLPC and 15-HETE
of PpargM / macrophages did not increase the killing of
C. albicans (Fig. 6f), corroborating our ﬁndings that PPARg is
downstream from LRH-1 in the signalling pathway triggered by
IL-13, leading to macrophage fungicidal activities.
To unequivocally establish that the LRH-1/CYP1/HETE axis is
involved in macrophage-intrinsic antifungal activity of IL-13, we
evaluated the ability of macrophages silenced for Cyp1a1 and
Cyp1b1 (Cyp1) to kill C. albicans. Interestingly, the increase in
C. albicans killing by IL-13 and DLPC was inhibited by the
simultaneous gene silencing for Cyp1a1 and Cyp1b1 (Cyp1), but
not after 15-HETE stimulation (Fig. 6g). Taken together, these
data provide in vivo evidence that LRH-1 is involved in the
PPARg-dependent antifungal functions elicited by IL-13 through
CYP1-induced 15-HETE production.
Discussion
The nuclear receptor PPARg is essential for IL-13-induced
alternative differentiation of macrophages6,28,29. We have
previously demonstrated that IL-13, via the cPLA2 signalling
pathway, induced AA mobilization associated with the nuclear
localization of 15d-PGJ2, an endogenous PPARg ligand5. Once
activated, PPARg induces the transcription of Dectin-1, MR
and CD36, three genes characteristic of the alternative
activation5,30,31. Therefore, the processes leading to PPARg
activation, such as AA release and its subsequent metabolic
conversion, could be important aspects of alternative polarization
because they are limiting factors for PPARg ligand synthesis.
AA can be metabolized by the COX1/COX2 cyclooxygenases
to PGH2, which in turn is transformed by the PGD synthase into
15d-PGJ2 (refs 32,33). AA can also be directly metabolized to
12- and HETEs, other endogenous PPARg ligands, through 12/15
lipoxygenases34. A third pathway of AA metabolism leading to
endogenous PPARg ligand production is associated with its
conversion by the enzymes of the CYP family35–37. The CYP
enzymes generate two biological and active classes of eicosanoids,
the epoxy (EETs) and hydroxy (HETEs) derivatives10,11. The
CYP1 family is mainly involved in the formation of mid-chain
HETEs, such as 12- and 15-HETEs, through CYP1A1 and
CYP1B1 (refs 12,13).
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Figure 5 | STAT6/LRH-1/PPARc signaling is required for IL-13-mediated alternative activation of macrophages. (a) Luciferase activity in peritoneal
macrophages from Lrh-1Mþ /þ and Lrh-1M / mice transfected with a PPRE (PPRE-luc) construct and treated with IL-13 or 15-HETE for 24 h.
(b) Gene expression analysis of Mrc1, Clec7a and Cd36 in macrophages from Lrh-1Mþ /þ and Lrh-1M / mice treated with IL-13 or 15-HETE for 4 h,
determined by RT–PCR. (c) Luciferase activity of macrophages from ALox15þ /þ and ALox15 / mice transfected with a PPRE (PPRE-luc) construct and
siRNA targeting Cyp1a1 and Cyp1b1 (siRNA Cyp) and treated with IL-13 for 24 h. (d) Gene expression analysis of Mrc1, Clec7a and Cd36 in macrophages
from ALox15þ /þ and ALox15 / mice transfected with siRNA targeting Cyp1a1 and Cyp1b1 (siRNA Cyp) treated with IL-13 for 4 h and determined by
RT-PCR. (e,g) Gene expression analysis of Arg1 (arginase 1), Retnla (Fizz1), Chi3l3 (YM1), Mrc1, Clec7a and Cd36 in macrophages from Stat6þ /þ and
Stat6 / mice (e) or from PpargMþ /þ and PpargM / mice (g) treated with IL-13 or 15-HETE (e) for 24 h, determined by RT-PCR. (f) 15-HETE
production by macrophages from Stat6 / and Stat6þ /þ mice stimulated with IL-13 for 24 h measured by EIA. (h) Gene expression analysis of Mrc1,
Clec7a and Cd36 in macrophages from PpargMþ /þ and PpargM / treated with DLPC for 4 h, determined by RT-PCR. Results were represented in fold
induction compared to the respective untreated control or wild-type littermate and correspond to mean±s.e.m. of triplicates. Data are representative of
three independent experiments. *Po0.05, **Po0.01 compared to the respective ﬂoxed or not untreated control and xPo0.05, xxPo0.01 compared to the
corresponding untreated or treated wild-type littermate or siRNA control. P values were determined using Bonferroni–Dunnett method.
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Here we report that the nuclear receptor LRH-1 is expressed in
macrophages and in response to IL-13 directly binds CYP1A1
and CYP1B1 promoters to positively regulate their transcription.
Moreover, 15-HETE production following IL-13 stimulation is
impaired in macrophages deﬁcient for LRH-1 and not in
macrophages lacking 12/15 lipoxygenase, indicating that LRH-1
drives the generation of 15-HETE metabolites through its impact
on CYP1 gene expression. Consistently, our ﬁndings showing that
the concurrent gene silencing of Cyp1a1 and Cyp1b1 in
macrophages abolishes the generation of 15-HETE, provide
evidence that its production through the LRH-1/CYP1s axis is
crucial in PPARg activation. This is corroborated by the ﬁndings
that PPARg activation on IL-13 stimulation is lost in macro-
phages silenced simultaneously for CYP1A1/CYP1B1 and
restored by the addition of exogenous 15-HETE in macrophages
lacking LRH-1. Consistent with these observations, treatment of
macrophages with the LRH-1 agonist, DLPC, increased the
expression of CD36, MR and Dectin-1 PPARg target genes in
wild-type macrophages but not in macrophages lacking PPARg.
Altogether, these results establish that PPARg activation by IL-13
is dependent on the LRH-1/CYP1/15-HETE pathway. Another
endogenous activator to consider in PPARg activation is 15d-
PGJ2. Although we have previously shown that IL-13 generates
15d-PGJ2 production and its nuclear localization in macro-
phages5, the results in this study suggest that it is not sufﬁcient to
activate PPARg. This is supported by previous reports showing
that 15d-PGJ2 concentration required to stimulate PPARg is in
the mM range, in contrast to other prostaglandins that are
normally active at low nM concentrations38,39. Thus, the levels
generated in vivo are not sufﬁcient to be compatible with a role
for this metabolite as an endogenous PPARg ligand38,40.
Despite the growing knowledge with regard to the biological
function of LRH-1, little is known about how LRH-1 is controlled
at the transcriptional level. We identiﬁed STAT6 as a transcrip-
tional regulator of LRH-1. This was evidenced by the induction of
LRH-1 promoter activity by binding of STAT6 to its RE in the
LRH-1 promoter and by the decrease in LRH-1 mRNA and
protein levels in macrophages lacking STAT6. On the basis of the
established role of STAT6 in PPARg activation and macrophage
polarization41, these ﬁndings identify LRH-1 as a critical
component in the signalling cascades that drive PPARg-
mediated alternative macrophage activation. This was further
highlighted by the fact that macrophages lacking LRH-1 present
an increase in pro-inﬂammatory cytokines and the simultaneous
expression of other M1 markers. The involvement of LRH-1 in
anti-inﬂammatory responses was supported by the robust
reduction of LRH-1 gene expression in response to Th1
cytokines and conversely by the upregulation by Th2 cytokines.
Interestingly, LRH-1 was also induced in human macrophages in
response to the Th2 cytokine IL-13 via a mechanism that is most
likely also STAT6-dependent, given the presence of several
conserved STAT6 REs in the human LRH-1 promoter
(Supplementary Fig. 3a). Our ﬁndings may further explain why
during Crohn’s disease, characterized by a Th1 cytokine proﬁle,
mRNA expression levels of LRH-1 are lower than in ulcerative
colitis, characterized by a Th2 immune response21. Consistent
with the anti-inﬂammatory role of LRH-1, IL-13-induced
alternative activation was impaired in macrophages lacking
LRH-1. Indeed, on IL-13 treatment, the induction of several
signature genes of alternative activation, including Arginase 1,
YM1, IL-1 receptor antagonist (IL-1ra), MR, Dectin-1 and CD36,
was signiﬁcantly impaired in macrophages lacking LRH-1. This is
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Figure 6 | IL-13-induced antifungal properties of macrophages require LRH-1. (a) Survival of Lrh-1M / and Lrh-1Mþ /þ mice to an intraperitoneal
injection of C. albicans (1.108 yeasts per mouse, n¼ 32 per group). Survival (%) was assessed twice daily. *Po0.001 compared with Lrh-1Mþ /þ mice using
log-rank test. (b) Lrh-1Mþ /þ and Lrh-1M / mice were infected with C. albicans, and treated i.p. without (C) or with IL-13, DLPC or 15-HETE. C. albicans
gastrointestinal colonization in the caecum was determined on day 7 using RT–PCR. Data are represented as mean±s.e.m. *Po0.05 compared with the
respective untreated control and xPo0.05 compared with the corresponding untreated or treated Lrh-1Mþ /þ . The data are representative of at least two
independent experiments (n¼ 10 per group). (c) Killing assay of Lrh-1Mþ /þ and Lrh-1M / macrophages incubated with C. albicans. (d,e) Phagocytosis
(d) and ROS induction (e) of C. albicans were measured in macrophages from Lrh-1M / and Lrh-1Mþ /þ mice. Data are expressed as fold induction
relative to the ﬂuorescence (c) or chemiluminescence (d) observed for untreated Lrh-1Mþ /þ . (f) Killing assay of PpargMþ /þ and PpargM /
macrophages incubated with C. albicans. (g) Killing assay of macrophages silenced for Cyp1a1 and Cyp1b1 incubated with C. albicans. *Po0.05, **Po0.01
compared with the respective untreated control and xPo0.05 xxPo0.01 compared with the corresponding treated wild-type littermate or siRNA control.
P values were determined using Bonferroni–Dunnett method. Results correspond to mean±s.e.m. of triplicates and are representative of at least three
independent experiments. For indicated measurements, treatments with IL-13, 15-HETE and DLPC were performed 24h before the challenge with
C. albicans.
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in agreement with reports showing that LRH-1 controls the
expression of anti-inﬂammatory IL-1ra and the scavenger
receptor class B type I, two markers speciﬁc of alternatively
activated macrophages22,23,42.
In addition to the key role of LRH-1 in the acquisition of
alternative activation of macrophages, this study also provides
mechanistic insight into the hierarchy between STAT6, LRH-1
and PPARg to achieve this phenotype. Our ﬁndings showing that
loss of induction of alternative activation markers in Stat6 /
macrophages can be restored by exogenous 15-HETE support the
notion that STAT6 is required for macrophage-alternative
activation through PPARg-dependent mechanism. Moreover,
the use of PpargM / macrophages provides evidence for the
existence of distinct mechanisms in the transcriptional regulation
of genes characteristics of alternative activation. Our results
demonstrate that the transcriptional regulation of Arginase 1,
Fizz 1 and YM1 involves directly STAT6 with a modest
contribution of PPARg and that Dectin-1, MR and CD36 are
regulated indirectly by STAT6 through the LRH-1/PPARg axis.
These observations are not only consistent with the requirement
of STAT6 to induce the majority of PPARg target genes41 but also
with the identiﬁcation of PPARg as a positive regulator of
alternative activation6.
Consistent with the involvement of the LRH-1/PPARg path-
way in inducing MR and Dectin-1 expression during IL-13-
mediated alternative activation, loss of LRH-1 and PPARg in
macrophages also severely compromised their capacity to kill, to
engulf C. albicans and to produce ROS. This is in line with the
fact that LRH-1 is upstream from PPARg in the signalling
pathway leading to the induction of MR and Dectin-1, two C-type
lectin receptors strongly involved in the antifungal functions of
macrophages against C. albicans5,27,31. LRH-1 deﬁciency in
myeloid cells also rendered the mice highly susceptible to
gastrointestinal and systemic C. albicans infection, highlighting
LRH-1 of myeloid lineage as a key effector of host fungicidal
functions. Although we have not characterized the role of
neutrophils in this infectious context, our in vitro and in vivo
results identify LRH-1 as a nuclear receptor indispensable for
alternative activation of macrophages and for its associated
antifungal functions.
In conclusion, we have shown that loss of LRH-1 in
macrophages prevents IL-13-induced alternative activation of
macrophages, demonstrating the pivotal role of LRH-1 in the
differentiation of macrophages towards an anti-inﬂammatory and
antifungal phenotype. In response to IL-13, LRH-1 expression is
increased in macrophages through STAT6 and controls the
expression of CYP1A1 and CYP1B1 enzymes, which catalyses the
generation of 15-HETE PPARg ligand. Altogether, these results
establish that the alternative polarization of macrophages by
IL-13 is dependent on the STAT6/LRH-1/CYPs/15-HETE/
PPARg axis (Fig. 7). Finally, deletion of LRH-1 in myeloid cells
renders mice susceptible to gastrointestinal and systemic C.
albicans infection, highlighting LRH-1 as a critical factor for
antifungal functions. Synthetic agonists of LRH-1 activity may,
hence, constitute promising compounds for the treatment of
anti-infectious and anti-inﬂammatory diseases.
Methods
Mice. Male mice aged 10–12 weeks on C57BL/6 background were used for in vitro
and in vivo experiments. Mice were bred and handled by following protocols
approved by the Conseil Scientiﬁque du Centre de Formation et de Recherche
Experimental Me´dico Chirurgical and the ethics board of the Midi-Pyre´ne´es ethic
committee for animal experimentation (Experimentation permit number 31–067,
approval no. B3155503). All cages were changed twice weekly, and all manipula-
tions of the animals were carried out in a laminal blow hood under aseptic con-
ditions. The photoperiod was adjusted to 12-h light and 12-h dark. C57BL/6 mice
were purchased from Janvier (France) and Stat6 / mice and ALox15 / mice
were purchased from Jackson Laboratories. PpargM / mice deleted for Pparg
speciﬁcally in macrophages have been described earlier30,43. Nr5a2 (encoding
LRH-1) macrophage speciﬁc knockout mice (referred as Lrh-1M / mice) were
obtained by crossing mice carrying ﬂoxed Lrh-1 alleles with transgenic mice
expressing the Cre recombinase under the control of the mouse phagocyte-selective
lysozyme promoter21,26. For Lrh-1M / and PpargM / mice, the
corresponding ﬂoxed littermates were used as controls throughout all the
experiments. Corresponding littermates were used as controls for Stat6 /
and ALox15 / mice.
For the in vivo experiments, a gastrointestinal infection with the C. albicans
strain was established by gavage with 50 106 C. albicans per mouse (n¼ 10 per
group). Mice were treated or not intraperitoneally (i.p.) with IL-13 (Clinisciences),
DLPC (Sigma) or 15-HETE (Cayman). For IL-13 treatment, injections of 4 mg per
mouse were performed 1 day before and 3 days after the infection with C. albicans
(two injections). For DLPC (300 mg per 10 g of mouse) and 15-HETE (28 mg per
10 g of mouse), i.p. injections were realized 1 day before the day of the infection
with C. albicans and then every 2 days (ﬁve injections). Control groups received
saline solution only with DMSO. After 6 days of infection, the ceca were removed
aseptically for the experiments.
For C. albicans systemic infection, yeasts were administered i.p.
(100 106yeasts per mouse). Survival studies were conducted using 32 mice
per group and were repeated twice.
Human macrophages. Monocytes were obtained from healthy blood donors
(Etablissement Franc¸ais du Sang, EFS Toulouse). Written informed consents were
obtained from the donors under EFS contract no. 21/PVNT/TOU/UPS04/2010–
0025. Following articles L1243-4 and R1243-61 of the French Public Health Code,
the contract was approved by the French Ministry of Science and Technology
(agreement no. AC 2009-921). Human peripheral blood mononuclear cells were
isolated from the blood of healthy volunteers by a density gradient centrifugation
method on Lymphoprep (Abcys). Monocytes were isolated by adherence to plastic
for 2 h in SFM (Gibco) at 37 C, 5% CO2. The macrophages were obtained after
3 days of culture only in SFM medium.
Preparation of mouse resident peritoneal macrophages. After being killed,
resident peritoneal cells were harvested by washing the peritoneal cavity with 5ml
of sterile NaCl 0.9%. Collected cells were centrifuged at 1,500 r.p.m. for 10min and
the cell pellet was suspended in Dulbecco’s modiﬁed Eagle’s medium (Invitrogen)
supplemented with glutamine (Invitrogen), penicillin, streptomycin (Invitrogen)
and 5% heat-inactivated fetal calf serum. Cells were allowed to adhere for 2 h at
37 C and 5% CO2. Nonadherent cells were then removed by washing with PBS.
Reverse transcription and real-time PCR. After washing, adherent macrophages
were immediately stimulated with IFNg (40UIml 1, Clinisciences), IL-6
(50 ngml 1, Clinisciences), LPS (1 ngml 1, Sigma), IL-4 (50 ngml 1, Miltenyi
Biotech), IL-13 (50 ngml 1, Clinisciences), IL-10 (50 ngml 1, Clinisciences),
15-HETE (1 mM, Cayman) or DLPC (50mM, Sigma) for 4 or 24 h. In indicated
experiments, adherent macrophages were pre-incubated or not with a Jak-2/STAT6
inhibitor, AG490 (1 nM, Tebu-Bio).
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Figure 7 | Schematic illustration of the role of LRH-1 in IL-13-alternative
activation program of macrophages and in associated fungicidal
activities. The alternative polarization of macrophages by IL-13 is
dependent on the increase of LRH-1 expression through STAT-6 which
controls the expression of Cyp1a1 and Cyp1b1 enzymes leading to the
generation of 15-HETE PPARg ligand.
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The mRNA preparation was made using the EZ-10 Spin Column Total RNA
Minipreps Super Kit (Bio Basic) using the manufacturer’s protocol. Synthesis of
cDNA was performed according to the manufacturer’s recommendations (Thermo
electron). RT–qPCR was performed on a LightCycler 480 system using LightCycler
SYBR Green I Master (Roche Diagnostics). The primers (Eurogentec) were
designed with the software Primer 3. Actb (Actin) mRNA was used as the invariant
control. Serially diluted samples of pooled cDNA were used as external standards
in each run for the quantiﬁcation. Primer sequences are listed in Supplementary
Table 1.
In situ hybridization. In situ hybridization was performed with digoxigenin-
labelled RNA probe (Plasmid pBSSK Lrh-1) as previously described44. Brieﬂy,
this manual nonradioactive method allows to detect speciﬁc complementary
mRNA sequences at the cellular level using digoxigenin-labelled probes in a
ﬁve-step procedure: hybridization of the probe to pretreated tissue at 65 C;
post-hybridization stringent washes; blocking steps to prepare for the
immunodetection; primary antibody anti-DIG-AP incubation; and colorimetric
enzymatic detection. The detection step lasts for 2–3 days.
Western blot analysis. Nuclear protein extracts were prepared, and lysates were
subjected to western blotting as described previously45. Brieﬂy, nuclear protein
lysates were extracted following standard procedures. Protein extracts were
separated using SDS–PAGE. After protein transfer, membranes were incubated
overnight at 4 C with either a rabbit anti-Lrh-1 (ref. 21; 1/1,000), a rabbit
polyclonal anti-Tbp (Abcam, ab63766, ½,000), a rabbit anti-Cyp1b1 (Santa Cruz,
sc-133490, 1/200) or a Actin (Santa Cruz, sc-1615, 1/1,000) and then for 1 h at
room temperature with a peroxidase conjugated secondary antibody. Membranes
were washed, and proteins were visualized with the SuperSignal West Pico
Chemiluminescent Substrate (ThermoScientiﬁc). Images have been cropped for
presentation. Full-size images are presented in Supplementary Fig. 4.
Transfection experiments. Macrophages were pre-incubated or not with AG490
(1 nM) and then incubated with 1 mg of DNA per well of the indicated plasmids
(pGL3 promoter LRH-1-luciferase, pCMX-LRH-1, PPRE luciferase, pGL3 pro-
moter PPARg-luciferase, pGL4.12 promoter Cyp1a1-luciferase or pGL4.12 pro-
moter Cyp1b1-luciferase) with JetPei (Polyplus transfection) for 8 h according to
the manufacturer’s instructions. Then, the cells were stimulated or not with IL-13
(50 ngml 1) for 18 h. Supernatant was removed, luciferase substrate was added
and luminescence was measured with the Envision luminometer (Perkin Elmer).
For siRNA experiments, mouse Cyp1a1 and Cyp1b1 and control siRNA were
purchased from Origene. Macrophages were incubated with 20 nM of control
siRNA or Cyp1a1 and Cyp1b1 siRNA and with Lipofectamine 2000 (Invitrogen)
for 18 h according to the manufacturer’s instructions. Cells were then stimulated
with IL-13, DLPC or 15-HETE for 18 h.
ChIP. ChIP analysis was performed as described previously with minor adapta-
tions46. Brieﬂy, the liver and colon from Lrh-1þ /þ and Lrh-1 / mice were
lysed (5mM PIPES pH 8.0, 85mM KCl, 0.5% NP40 with protease inhibitors). The
pellets or adherent macrophages from indicated mice were cross-linked with 1%
formaldehyde for 15min at room temperature. The cells were then lysed in nuclear
lysis buffer (50mM Tris-HCl pH 8.1, 10mM EDTA, 1% SDS with protease
inhibitors) and sonicated at 30% maximum power eight times. The supernatant
was diluted in immunoprecipitation-dilution buffer (0.01% SDS, 1.1% Trition
X-100, 1.2mM EDTA, 16.7mM Tris-Cl pH 8.1 and 167mM NaCl with protease
inhibitor) and precleared with Protein A agarose/salmon sperm DNA beads
(Invitrogen 101141). The samples were immunoprecipitated overnight at 4 C with
a rabbit Lrh-1 antibody21, normal rabbit IgG (Santa Cruz, sc-2027, 7 ml/ml) or with
a rabbit STAT6 antibody (Santa Cruz, sc-981, 7 ml ml 1). The beads were then
washed in low-salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM
Tris-HCl pH 8 and 150mM NaCl), high-salt buffer (0.1% SDS, 1% Triton X-100,
2mM EDTA, 20mM Tris-HCl pH 8 and 500mM NaCl) and LiCl buffer (1%
NP40, 1% deoxycholate, 1mM EDTA, 10mM Tris-HCl pH 8 and 250mM LiCl).
The samples were then boiled in chelex followed by incubation with proteinase K
solution (10 mgml 1 proteinase K; 10mM EDTA; and 37mM Tris-HCl, pH 6.5) at
55 C for 30min. DNA was puriﬁed using the EZ-10 Spin Column Total RNA
Minipreps Super Kit (Bio Basic), after which qPCR was performed. Data were
normalized for GAPDH promoter binding and expressed relative to IgG. ChIP
primer sequences are listed in Supplementary Table 2.
Reporter assays and site-directed mutagenesis. Genomic DNA was extracted
from mouse kidneys and the corresponding Cyp1a1 and Cyp1b1 promoter frag-
ments were ampliﬁed by PCR with primers containing KpnI and XhoI restriction
sites. The PCR products were then cloned into pENTR-D/TOPO (Invitrogen/
Lifetechnologies) plasmids, which were digested with KpnI and XhoI and then
ligated into pGL4.12 (Promega) reporter plasmids.
Mutagenesis was carried out with the GeneArt mutagenesis kit (Invitrogen/
Lifetechnologies) according to the manufacturer’s instructions. The sequences of
reporter constructs were analysed and conﬁrmed.
Flow cytometry. The analysis was performed on nonadherent macrophages47
harvested by washing the peritoneal cavity with 5ml of sterile NaCl 0.9%. Collected
cells were centrifuged at 1,500 r.p.m. for 10min and the cell pellet was suspended in
PBS medium supplemented with 1% fetal calf serum (FCS). Surface expressed
Dectin-1 or CD36 was detected, respectively, using ﬂuoroscein isothiocyanate
(FITC)-Dectin-1 monoclonal antibody (mAb; Serotec MCA2289F, 1/100) or
PE-CD36 mAb (Santa Cruz, sc-13572, 1/100) and was compared with an irrelevant
appropriate isotype control. To evaluate the mannose receptor (MR) surface
expression, we have used MR-speciﬁc ligand conjugated with FITC (Sigma A7790,
1mgml 1). All stainings were performed on PBS—1% FCS medium. A population
of 10,000 cells was analysed for each data point. All analyses were carried out in a
Becton Dickinson FACScalibur using the CellQuestPro software.
B and T lymphocytes were isolated from the mouse spleen with a PE-B220 mAb
(RD System FAB1217P, 1/10) and a PE-CD3 mAb (eBiosciences MCA500, 1/10)
using a Becton Dickinson Inﬂux cell sorter.
ELISA Cytokine titration and EIA quantiﬁcation of 15-HETE. Peritoneal
macrophages were stimulated with IL-13 for 18 h and challenged with non-
opsonized C. albicans at a yeast-to-macrophage ratio of 3:1 for 8 h. The production
of TNF-a, IL-1b and TGF-b in the cell supernatants was determined with
a commercially available OptiEIA kit (BD Biosciences) according to the
manufacturer’s instructions.
For 15-HETE quantiﬁcation, the macrophages were stimulated with IL-13 for
18 h and 15-HETE were measured using EIA as recommended by the
manufacturer’s protocol (15(S)-HETE EIA kit, Cayman).
AA mobilization. Peritoneal macrophages were prelabelled with [3H]AA (1mCi
per well, Perkin Elmer) for 18 h. The prelabelled macrophages were then treated
with IL-13 (50 ngml 1) for 1 h. The cellular lipids were extracted twice with
hexane/isopropanol (3:2, v/v) and the [3H]AA content in membrane phospholipids
was quantiﬁed by measurement of the radioactivity by beta liquid scintillation
counting, as described with minor adaptations48.
C. albicans strain. The strain of C. albicans used throughout these experiments was
isolated from a blood culture of a Toulouse-Rangueil Hospital patient5. Fluorescent
C. albicans was prepared by adding C. albicans to FITC (Sigma) dissolved in sodium
carbonate buffer (pH 9.5) at room temperature for 3 h and washed by centrifugation
three times in sodium carbonate buffer before storage in aliquots of water at 4 C.
Phagocytosis assay and ROS quantiﬁcation. For analysis of phagocytosis of
C. albicans, cultured macrophages were pretreated or not with IL-13, 15-HETE or
DLPC for 18 h and then challenged with six FITC-labelled yeasts per macrophage.
Phagocytosis was initiated at 37 C with 5% CO2 and stopped after 1 h by washing
the macrophages with ice-cold PBS. The number of C. albicans engulfed by
macrophages was determined with ﬂuorescence quantiﬁcation using the Envision
(Perkin Elmer) ﬂuorimetry-based approach.
The oxygen-dependent respiratory burst of macrophages (ROS production) was
measured by chemiluminescence in the presence of 5-amino-2,3-dihydro-1,4-
phthalazinedione (luminol) using a thermostatically (37 C) controlled
luminometer (Wallac 1420 Victor2). The generation of chemoluminescence was
monitored continuously for 1 h after incubation of the cells with luminol (66 mM)
and pretreatment with IL-13, 15-HETE or DLPC for 18 h and challenge with C.
albicans (yeast-to-macrophage ratio: 3:1). Statistical analysis was performed using
the area under the curve expressed in counts  seconds.
Killing assay. The killing assay was performed as previously described49. Cells were
allowed to interact for 30min at 37 C with C. albicans (at a ratio of 0.3 yeast per
macrophage) and unbound yeasts were removed by four washes with medium.
Macrophages were then incubated at 37 C for 4 h. Control plates were kept at 4 C
to provide a measure of live C. albicans in the wells. After incubation, the medium
was removed and cells were lysed by incubation for 5min at 25 C with water at a pH
of 11. An excess of PBS was used to neutralize the lysis buffer, and CFU C. albicans
was determined by plating on Sabouraud plates and incubation overnight at 37 C.
Quantiﬁcation of C. albicans in the caecum. Cell lysis and DNA extraction. After
mouse infection, ceca were aseptically removed and then crushed using lysing
matrix tubes (MP Biomedicals). Tissue sample homogenate (250 ml) was
resuspended in 200ml of lysis buffer for 2 h at 65 C and DNA was then extracted
with isopropanol and eluted with an elution buffer (High Pure PCR Template
preparation kit, Roche Diagnostics).
Light cycler-based PCR assay. The Light Cycler PCR and detection system
(Roche Diagnostics) was used for ampliﬁcation and online quantiﬁcation. PCR
analysis was performed as described previously27. Serially diluted samples of
genomic fungal DNA obtained from C. albicans cultures (40 106 cells) were used
as external standards in each run. Cycle numbers of the logarithmic linear phase
were plotted against the logarithm of the concentration of template DNA to
evaluate the number of yeast cells present in each tissue sample homogenate.
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Statistical analysis. For each experiment, the data were subjected to one-way
analysis of variance followed by the means multiple comparison method of
Bonferroni–Dunnett. For survival study, statistical signiﬁcance was determined by
a log-rank test. Po0.05 was considered as the level of statistical signiﬁcance.
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